Denali will sponsor a satellite symposium event titled “Transforming Patient Care in MPS II” on Thursday, February 5, 2026, ...

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The ...

Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical ...

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study ...

Researchers at University of Tsukuba and their collaborators have demonstrated that learning from both rewarding and aversive ...

Asthma may not be driven by the molecules scientists have blamed for decades. Researchers have identified “pseudo leukotrienes,” inflammation-triggering compounds formed by uncontrolled free-radical ...

First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and ...

First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAHSAN DIEGO, Jan. 22, 2026(Nasdaq: CRNX) today anno ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...

DelveInsight's PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast report includes ...

Scientists at UC Davis created a new class of serotonin-targeting molecules using a light-driven chemical method. UC Davis scientists have created a light-based technique that converts amino acids — t ...

Drug discovery is shifting from static snapshots to moving pictures. Instead of inferring how medicines work from end results ...